CTRI/2014/01/004277已完成未知
A Prospective, Double Blind, Randomised, Two Arm, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Two Proprietary Herbal Medicines as Mono Therapy and as Combination Therapy in Adult Subjects with Moderate to Severe Psoriasis.
Dr JRKs Siddha Research and Pharmaceuticals Private Limited0 个研究点目标入组 42 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male and Female Adults between the ages of 18 and 50.
- •2.Psoriasis Body Surface Area at baseline is between >=3%
- •3.Subject who understand and willing to sign informed consent document before start of any study specific assessment.
- •4.Subjects who are willing not to participate in any other clinical trial during participation in the current trial.
- •5.Subject has not participated in a similar investigation in the past four weeks.
排除标准
- •1.Subjects with Psoriatic Arthritis.
- •2.Ongoing topical treatment or remedial measures for psoriasis inclusive of creams, lotions and oils 2 weeks before inclusion into the study.
- •3.Subjects currently receiving drugs like Lithium, B- blockers, Antimalarials and NSAIDs or using corticosteroids and anti-inflammatory medicines until 15 days before inclusion into the study.
- •4.Subjects are using DMARDS or are on Psoralen+UVA - Phototherapy 4 weeks prior to inclusion into the study.
- •5.Subject with history of cancer including skin cancer.
- •6.Subject with serious dermatological infection in past three months requiring systemic therapy.
- •7.Subjects with facial melasma, lesions and other types of skin damage that is not psoriasis.
- •8.History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection.
- •9.History of opportunistic infections (e.g., systemic fungal infections, parasites)
- •10.Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, severe cardiovascular, pulmonary, (especially COPD where steroid treatment is required), cerebral, hematologic, neurological or psychiatric disease.
- •or any other serious medical illness.
- •11.A known history or present condition of allergic response to any cosmetic products.
- •12.Females who are pregnant or lactating or planning to become pregnant during the study period.
- •13.Subjects who maybe allergic to any of the natural constituents of the Investigational Product.
- •14.Subjects, who in the opinion of the Investigator or the Medical Experts are not eligible for enrollment in the study.
研究者
相似试验
已完成
2 期
Clinical study of JPT-25 capsules in people with smoking habitsCTRI/2017/06/008787Gurseet Singh103
招募中
3 期
To evaluate the safety and efficacy of Liv.52 tablets in alcoholic patientsCTRI/2022/07/044203Himalaya Wellness Company
进行中（未招募）
1 期
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 14.1Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865EUCTR2012-002215-26-ESAbbott Laboratories GmbH1,066
进行中（未招募）
1 期
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 15.1Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865EUCTR2012-002215-26-BEAbbott Laboratories GmbH1,066
进行中（未招募）
1 期
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 19.0Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865EUCTR2012-002215-26-ATAbbott Laboratories GmbH1,066